Non-antibiotic interventions can be used as an effective blanket treatment to ‘dry-off’ cows, according to new research.
The work, commissioned by AHV International, was undertaken by WIT Honours’ degree student, Nicole Keohane, in collaboration with staff at the IT.
According to AHV International, the use of this approach can deliver a beneficial impact on somatic cell count (SCC) levels for a significantly longer period into the new lactation than one would normally expect from antibiotic-based ‘dry cow’ therapies.
Alternative to blanket DCT
Courtesy of the study, the AHV Extra Tablet was evaluated as an alternative to blanket dry cow therapy (DCT).
A total of 33 cows were assigned alternately to blanket DCT or the AHV Extra Tablet treatment based on their SCC scores prior to drying off. An equal range of high, medium and low SCC cows was used for each treatment.
17 cows were administered the AHV Extra Tablet on November 20th, 2019, three weeks prior to dry-off. Approximately half of the cows were also teat sealed at dry-off on December 11th.
The remaining 16 cows were treated with blanket DCT (antibiotic and teat sealer) on December 11th.
Each treatment group contained an equal mix of high (< 400,000 cells/ml), medium (201,000 – 400,000 cells/ml) and low (< 200,000 cells/ml) SCC cows. One of the 16 cows within the DCT group died post-parturition. This was unrelated to the treatment programme.
As Nicole points out, the results of the trial shed new light on how dairy cows should be managed at dry-off.
She explained: “All the cows on the trial, which were due to calve in February of this year, were cell count tested on November 7th. Those receiving the AHV tablet were also drenched with the company’s Aspi anti-inflammatory.”
“The control cows were treated with a standard antibiotic dry cow therapy and teat sealed. All cows across both groups were subsequently cell count tested on February 14th, March 7th, and April 8th.”
“Success in the trial was defined in the context of a cow with an SCC value of fewer than 200,000 cells/ml at the first test after calving.”
“The results confirm that the AHV Extra Tablet treatment was successful in 92.88% of the low SCC cows, whereas the blanket DCT was only successful in treating 50% of this population.”
“Both treatments performed similarly in medium SCC cows at the first milk recording. The Extra Tablet was an effective dry cow therapy in 50% of these cows, and comparably the blanket DCT was effective in 50% of cows treated in this way.”
In subsequent milk recordings, the Extra Tablet treated cows continued to see a fall in SCC, with no sharp increases recorded. “However, the blanket DCT cows saw a noticeable spike in SCC in subsequent milk recordings.”
Nicole then referenced the one outlier cow in the trial. “This animal had an SCC of 9,993,400 cells/ml when tested on November 7th last year. She received an Extra Tablet and Aspi and subsequently recorded an 84.4% SCC reduction at the point of calving.
“She actually calved down at 1,560,000 cells/ml and continued to decline to 29,000 cells/ml over the subsequent 12 weeks without further treatment.”
“All the cows on the AHV treatment plan registered consistently lower SCC values up to the beginning of April, when the trial ended, compared with those on the more traditional antibiotic DCT treatment.
“The trial also confirmed that teat sealing had no effect whatsoever on the success of the Extra Tablet.”
According to Nicole, the results of the trial confirm the role of non-antibiotic treatments in safely managing all dairy cows at drying-off.
“Recent analysis of sales data in Ireland indicated that the sales of dry cow tubes were sufficient to treat 100% of the national milking herd.”
Changes in 2022
“Given the changes that will be introduced, which will severely restrict the use of these treatments from the beginning of January 2022, the need for alternative dry cow management procedures is obvious.”
“However, the good news is that the WIT trial confirms the potential for Irish dairy farmers to use the AHV Extra Tablet in this context.”
Nicole pointed to the need for the AHV trial to be repeated on a larger group of cows which is already underway. She also highlighted the worrying trend of cows becoming resistant to antibiotic treatments.
“This is the only reason to explain why the DCT cows registered a consistently high cell count after calving than those receiving the Extra Tablet.”
Repeating independent trials
AHV Managing Director, Adam Robinson said The WIT results fully confirm the results that farmers throughout Ireland have been seeing for themselves over the past two years.
“One thing I would point out is that we recommend administering the AHV Extra Tablet 4-6 weeks prior to drying off to allow the active biomolecules and the animals own immune system to effectively deal with the udder health challenge.”
“We know this already and we can see it in the results as the cow’s progress in early lactation. This is already planned for the next independent trials.”
“The AHV range is already a proven option on thousands of dairy farms within Ireland and the UK. The important role of AHV is educating the farmers on how to use the solutions correctly.”
“By using the AHV Extra Tablet, you are preparing the cow for the next lactation, and for a spring-calving herd, this starts now. Not the day of drying off.
Conventional DCT becoming less successful
“Most dairy farmers know that AMR is becoming a big problem and conventional DCT has become less successful over the years. There is plenty of data in the marketplace giving evidence to this fact.”
“But even this approach does not take away the risk of cows calving early and having to dump milk to prevent contaminated milk getting into the bulk tank.”
“The good news is that AHV Solutions can be used as either selective or blanketed across the herd. Either way, there is no risk of contaminating the bulk tank and your cows will start earning you money straight away.”
“A mention of thanks to Nicole for her hard and dedicated work on this project. I would like to thank WIT, in particular, Mr Mike Walsh for his involvement and input into the trial.”